Concepedia

Effects of Dapagliflozin on 24-Hour Glycemic Control in Patients with Type 2 Diabetes: A Randomized Controlled Trial

Robert R. Henry, Poul Strange, Rong Zhou, Jeremy Pettus, Leon Shi, Sergey B. Zhuplatov, Traci A. Mansfield, David J. Klein, Arie Katz

Diabetes Technology & Therapeutics · 2018 · 79 citations · 20 references

DOIFull text

Open access

Abstract

Compared with placebo, dapagliflozin improved measures of glycemic control and variability as assessed by CGM. Glycemic improvements were more pronounced in the group on background metformin than those receiving basal insulin.

References

20

Activation of Oxidative Stress by Acute Glucose Fluctuations Compared With Sustained Chronic Hyperglycemia in Patients With Type 2 Diabetes

Louis Monnier, Emilie Mas, Christine Ginet et al. · JAMA · 2006 · 2.4K citations

Mean Amplitude of Glycemic Excursions, a Measure of Diabetic Instability

F. John Service, George D. Molnar, John W. Rosevear et al. · Diabetes · 1970 · 1K citations

, , +16

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

Clifford J. Bailey, Jorge Luiz Gross, Anne Pieters et al. · The Lancet · 2010 · 848 citations

, , +6

Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of Insulin

John Wilding · Annals of Internal Medicine · 2012 · 459 citations

Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus

Bernard J. Komoroski, N. Vachharajani, L Li et al. · Clinical Pharmacology & Therapeutics · 2009 · 383 citations